AstraZeneca sells rights to high cholesterol treatment for up to US$350mln
Germany's Grünenthal will be able to sell Crestor in over 30 countries in Europe, except the UK and Spain
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 6 of 11
AstraZeneca gets upgrade from UBS but 2021 "won't be plain sailing"
After a fall in the shares they are now on a more “palatable” 13% premium to the sector based on 2024 forecast earnings
What are the concerns with the COVID-19 vaccine developed by AstraZeneca and Oxford University?
The results announced earlier this week have sparked criticism across the scientific community
AstraZeneca mulls new coronavirus vaccine trial following results confusion
The pharma giant will look to confirm the 90% efficacy rate the vaccine candidate showed in a questioned portion of initial trials
AstraZeneca faces criticism over COVID-19 vaccine trials results
In the trial that achieved 90% efficacy, there were only 2,300 participants all aged below 55
Will AstraZeneca rebound after slipping on Monday’s COVID-19 vaccine news?
The pharma giant could reap the long-term benefits from higher reputation – ‘no vax’ movements aside – and the economic ties with governments worldwide
Archive
Today's Market View - Anglo Asian Mining: Bezant Resources; Bushveld Resources; Kingston Resources; Vast Resources and more...
Economics US – President Trump hinted at transfer of power to President-elect Biden asking hi administration to cooperate with the transition team . President recommended the General Services Administration that provides transition resource
What are the differences between the COVID-19 vaccines developed by AstraZeneca, Pfizer and Moderna?
The FTSE 100 firm dipped after posting lower efficacy than its competitors, but the upside lies in the bigger picture
AstraZeneca says coronavirus vaccine is 90% effective in one dosing regimen
The jab protected participants from the virus 14 days or more after receiving two doses of the vaccine
AstraZeneca says Imfinzi cancer treatment approved for less frequent dosing option
Patients will be able to go to hospital to receive treatment once per month rather than every two weeks
AstraZeneca COVID-19 vaccine shows encouraging phase II results in peer-reviewed study
Data on the final stage of clinical trials is expected soon
AstraZeneca to release COVID-19 vaccine data imminently, says Jefferies
Analysts said the results should come in “days to weeks” after discussing with the pharma giant’s chief financial officer Marc Dunoyer
Archive
AstraZeneca shares in demand after HSBC upgrade
Nudging up the valuation by 140p to 7,260p each, the bank said the main oncology pillars of the group – Lynparza, Tagrisso and Imfinzi – showed robust growth in the third quarter
AstraZeneca posts positive late-stage trial results for asthma treatment
The drug candidate, developed with Amgen, was found to be effective and safe
Coronavirus: Hospitals told to be ready for COVID-19 vaccine by month-end
It would first be distributed to care home residents, people over 80 and healthcare workers
AstraZeneca receives EU approval for leukaemia treatment
The green light follows positive results from two Phase III clinical trials and a recommendation for approval by an EU committee
AstraZeneca's Brilinta get approval for use in stroke alongside aspirin
The US Food & Drug Administration green light followed a successful phase III study of the drug, also known as ticagrelor, in combination with aspirin
AstraZeneca posts lukewarm quarterly results as two candidates get EU approval
The drugs firm said it is on track to achieve full-year results in line with guidance despite quarterly revenue only being up 3%
Small chance of vaccine by Christmas says head of Oxford/AstraZeneca trial
Reports yesterday suggested the GPs had been told to prepare to administer a COVID-19 vaccine before Christmas.
AstraZeneca to sell heart failure treatment commercial rights for US$400mln
The buyer is German pharma company Cheplapharm while the agreement will cover over 70 countries
AstraZeneca says COVID-19 vaccine candidate provokes similar immune response in older, younger adults
Efficacy read-outs from the final phase of trials are expected "between now and the end of the year"
London hospitals told to be ready to receive AstraZeneca COVID-19 vaccine: media reports
Health Secretary Matt Hancock said vaccinating health workers was not his “central expectation” though he did not rule it out
AstraZeneca says Tagrisso granted priority review in US
It is being investigated as an additional treatment of patients with early-stage non-small cell lung cancer
AstraZeneca receives recommendation for approval for two candidates from EU committee
The recommendation was based on final-stage trial results for both Forxiga and Trixeo Aerosphere
AstraZeneca to begin late-stage trials on COVID-19 antibody prevention candidate
The US government has provided funding of US$486mln to progress the studies
Liberum hikes target price for AstraZeneca on Daiichi Sankyo collaboration prospects
The pair are developing cancer drug DS-1062 as part of a US$6bn partnership
Coronavirus: CEPI creates labs network to standardise vaccines testing
The organisation partnered with five clinical laboratories worldwide
AstraZeneca coronavirus vaccine to face deeper scrutiny by US regulator
A trial of the vaccine has already been halted in the US
AstraZeneca granted breakthrough therapy designation for Farxiga
The candidate showed promising results in early trials
AstraZeneca and GlaxoSmithKline shares still a good investment, says Berenberg
Big pharma is forecast to return 46% of operating cash flow in the form of dividends and 10% in share buybacks between 2020 and 2024
Vaccines remain the key as coronavirus second wave anxiety mounts among investors
There are more than six vaccines in late-stage trials currently
Archive
AstraZeneca criticised by US experts over COVID-19 vaccine trial halt
US scientists are concerned about the potential neurological adverse effects of the jab
AstraZeneca receives double EU recommendation for cancer drug
Lynparza is recommended for marketing authorisation for ovarian and prostate cancer, while Tagrisso showed positive results in late-stage trials for lung cancer
AstraZeneca resumes coronavirus vaccine trials in the UK
The Medicines Health Regulatory Authority has advised it was safe to restart the tests
Archive
The week in coronavirus: UK infection rate grows as AstraZeneca halts vaccine trials
A look at the week's major news regarding the pandemic
AstraZeneca to move to Nasdaq from New York Stock Exchange
The pharma giant is looking to cut costs, while it also announced “high-level” results for its rhinosinusitis candidate
AstraZeneca pauses Oxford coronavirus vaccine trial after adverse effect
The pharma giant said it is standard routine to allow review of safety data to ensure the integrity of the trials
Archive
FTSE 100 closes ahead as investors return to 'buy the dip' mode
Britain's top share index closed over 82 points higher at 6,012 midweek
Coronavirus: Australia secures two deals to roll out 85mln vaccine doses next year
Both agreements, for a UK formulation and a local one, are worth £900mln
AstraZeneca receives EU approval for Imfinzi for extensive-stage small cell lung cancer
The pharma giant also announced exceptional results for Farxiga in patients with chronic kidney disease
AstraZeneca agrees to supply 300mln COVID-19 vaccine doses to EU
The deal includes an option for a further 100 million doses
The runners in the COVID-19 vaccine race
A round-up of the most promising candidates to help immunise the world's population to end the pandemic
Oxford coronavirus vaccine potentially submitted to regulator this year, says scientist
Partner AstraZeneca has also denied discussions with US authorities for a fast-track approval
AstraZeneca kicks off in-human trial for coronavirus treatment using monoclonal antibodies
AZD7442’s combination of mAbs was derived from convalescent patients with SARS-CoV-2 infection
Archive
FTSE 100 closes in the red as hopes of a speedy vaccine are dashed
Britain's blue chip benchmark erased most of yesterday's gains to close down over 67 points at 6,037, down 1.11% on the day
Archive
Apple and tech stocks drive US markets to record highs
All three US benchmarks finished higher in New York, while Apple increase 1.2% to $503 a share
AstraZeneca says Imfinzi approved as lung cancer drug combination in Japan
In the first half of 2020, Imfinzi was one of the company's best-selling medicines, generating US$954mln of revenues
Coronavirus latest: Vaccine arm's race continues as EU holds talks with CureVac over bumper order
The EU is also in talks with Johnson & Johnson and Sanofi and has agreed advanced purchase deal with AstraZeneca for at least 300mln shots of the drug it is developing with the University of Oxford
AstraZeneca to issue debt at 0.7% interest rate
The issue is part of a three-tranche global bond offering totalling $3bn that is expected to close on 6 August.
AstraZeneca's new medicines continue to drive growth in first half
Oncology continued to be the star, growing sales 28% to US$5.3bn or 42% of total group revenue
Archive
FTSE 100 closes in the red; Wall Street struggles on grim GDP outlook
The index of UK blue-chips dropped 142 points to finish at 5,990
Archive
Coronavirus vaccines and oil dividends in focus on Thursday as AstraZeneca and Shell update investors
AstraZeneca, Shell and Lloyds are among the notable names in Thursday's diary.
AstraZeneca says chronic kidney disease drug passes final stage trial with flying colours
Farxiga was reported to show “a statistically significant and clinically meaningful effect” to prevent renal function from worsening or risk of death
AstraZeneca enters multi-billion oncology collaboration with Daiichi Sankyo, gets one step closer to EU approvals
The pair will jointly develop and commercialise a candidate for non-small cell lung cancers and breast cancers
AstraZeneca, Shell, Lloyds and other banks under the microscope in busy results week
Other updates are expected from BT, GSK, Next, Ryanair and Aston Martin, plus a US Fed meeting and a busy Wall Street earnings week including Apple and Alphabet
AstraZeneca pays US$150mln milestone as COPD treatment Breztri Aerosphere gets US approval
Breztri Aerosphere, a triple-combination inhaled treatment, showed significant improvements over dual-combination therapies in the phase III KRONOS/ETHOS trials.
Impossible to tell yet which potential coronavirus vaccine will work best, analysts say
Claims that the Oxford-AstraZeneca vaccine offers “dual protection” is totally unsubstantiated
Archive
FTSE 100 closes marginally ahead as EU rescue package cheers, gold sparkles
Britain's blue-chip benchmark finished the day up around eight points, or 0.13%, at 6,268
AstraZeneca and Oxford University vaccine triggers immune response in trial
The UK has already ordered 100 million doses of the vaccine, called AZD1222
AstraZeneca receives EU approval for Lynparza to treat metastatic pancreatic cancer mutation
The treatment targets the 5-7% of patients with pancreatic cancer who have a germline BRCA mutation
Coronavirus vaccines: Oxford candidate could be ready by autumn, flu season may wreak havoc in the winter, Australia to start first clinical trials…
Thursday's main news on vaccines development to tackle the pandemic
FTSE 100 dividend looks attractive but beware the concentration risk
Just ten blue chip stocks are forecast to pay 55% of the index's forecast total for 2020
AstraZeneca to supply up to 400 million coronavirus vaccine doses to EU countries
Deliveries will begin at the end of 2020 to countries wishing to take part in the initiative
Why do vaccine trials take so long?
It can even take a decade to find a suitable formulation against a certain disease, so reaching the final phase of trials in a matter of months is "unbelievably quick", says top scientist
AstraZeneca and Gilead Sciences merger hard to square say analysts
“Gilead needs a pipeline (which AZN has) and AZN could be looking for cash, not least to cover its dividend,”
AstraZeneca cools speculation over merger with Gilead Sciences
A deal would create a business worth around US$240bn and bring together two of the companies leading the way in the fight against coronavirus.
Archive
FTSE 100 closes in red after quiet session and excitement after Friday's jobs report wears off
Britain's blue chip benchmark finished down over 11 points at 6,472 having been in positive territory earlier
AstraZeneca reaches 2bn capacity for coronavirus vaccine doses, receives more funds from Bill Gates’ organisation
The pharma giant is producing the candidate developed by Oxford University, which is to release results on the second phase of trials by next month
AstraZeneca’s target price raised by UBS but Tagrisso margin implied in stock is out of reach
Analysts confirmed the forecast of US$8bn yearly sales but US$12bn upside “is going to be tough”
AstraZeneca in triple dose of positive results on cancer candidates
The pharma giant shared news on Enhertu, Imfinzi and Tagrisso, with the latter showing impressive results on reducing the risk of death in patients with a certain type of cancer
AstraZeneca raises hope for cure for non-small cell lung-cancer after stunning trial results
Tagrisso reduced the risk of disease recurrence or death by 83%
Coronavirus: UK begins anti-malaria drug trials as busy beaches spark controversy
The latest developments on the pandemic around the world
AstraZeneca boosts capacity for coronavirus vaccine candidate, receives US$1bn in US funding
Expenses for the vaccine, which will not be produced for a profit during the pandemic, are expected to be offset by funding by governments
Coronavirus: Moderna Inc announces positive interim results on vaccine candidate
The latest developments on projects to tackle the pandemic
AstraZeneca’s Enhertu fast-tracked for lung cancer treatment
The pharma giant also announced Bevespi Aerosphere was approved in China for patients with chronic obstructive pulmonary disease
AstraZeneca receives US approval for a combination with Lynparza in advanced ovarian cancer
The firm also announced it completed the recovery of global rights to brazikumab while its candidate Enhertu received a fast-track designation
AstraZeneca says Farxiga heart drug receives US green light
Farxiga has been shown to reduce the risk of death and hospitalisation for cardiovascular patients with a condition called reduced ejection fraction
AstraZeneca agrees to produce Oxford University’s coronavirus vaccine candidate on not-for-profit basis
The pharma giant would be responsible for the development and worldwide manufacturing and distribution of the candidate, if and when it is approved
AstraZeneca maintains guidance after strong start to year, buoyed by fast-growing oncology portfolio
It is also said it is committed to a progressive dividend policy
AstraZeneca PLC may be the UK's largest company, but it and other pharma giants rely in small-cap biotech for new medicines, according Arix pair
Arix is a backer of innovative smaller life sciences companies developing potentially breakthrough new medicines
AstraZeneca cancer drug passes prostate trial milestone
Lynparza successfully achieved a second goal when deployed to treat men with an advanced form of the disease
AstraZeneca to trial blood cancer drug for coronavirus treatment
“This is the fastest launch of any clinical trial in the history of AstraZeneca," according to José Baselga, the group's executive vice president in the oncology research and development segment
AstraZeneca’s target price upped to 8,870p by Liberum over oncology pipeline potential
The broker, which retains a 'buy' recommendation, said the pharma giant is expected to be “a long-term outperformer”
AstraZeneca stops chronic kidney disease treatment trial early after “overwhelming efficacy”
The pharma company also announced Imfinzi has been approved for small cell lung cancer in combination with chemotherapies
Archive
Small cap movers: Genedrive skyrockets with coronavirus test production ramp-up
A look back at some of the more interesting stories from London's junior market this week
AstraZeneca posts negative results for late-stage bladder cancer treatment
The base drug for the treatment is being tested in conjunction with chemotherapy in patients with the same disease
AstraZeneca completes sale of hypertension drugs rights
The initial US$350mln payment may be followed by optional instalments of up to US$40mln based on sales
AstraZeneca sells rights for constipation drug to RedHill Biopharma
AstraZeneca will retain rights to sell Movantik in Europe, Canada and Israel
AstraZeneca revenues surge ahead but coronavirus clouds current year
Sales will be driven by cancer drugs Enhertu, Lynparza and selumetinib in various markets and anaemia treatment Roxadustat in China
Archive
FTSE 100 closes lower as coronavirus fears and corporate updates hit equities
Britain's blue-chip index closed down nearly 43 points at 7,409. The FTSE 250, conversely, went higher, gaining over 116 points at 21,790
Archive
AstraZeneca and Royal Bank of Scotland on the cards for Valentine’s Day
The two FTSE 100 constituents are scheduled to release their final results
Can AstraZeneca, Barclays and RBS's numbers provide a shot in the arm?
Other updates on the coming week's agenda include Ocado, TUI, Babcock and Dunelm
AstraZeneca takes back autoimmune drug, sells rights to blood pressure treatments
The new arrangement will see Allergan still fund the development costs incurred by AstraZeneca
AstraZeneca's Imfinzi granted orphan status as liver cancer treatment
Imfinzi and tremelimumab are now 'orphan drugs', meaning their development becomes a matter of public policy because they cure a rare disease
Mixed picture for UK pharma as AstraZeneca ‘top pick’ at Credit Suisse while GlaxoSmithKline knocked by Barclays downgrade
Credit Suisse said AZN's “top-line growth and underlying margin potential” made it the top firm in their assessments
AstraZeneca earnings to be hit by US$100mln write-down after trial stops
An independent data monitoring committee recommended to stop phase III of the trial on Epanova, which is still marketed in the US for other treatments
AstraZeneca weighs in with a double dose of good news
It has received a fast-track review of a diabetes drug while gaining approval for a blood treatment in China
AstraZeneca and Merck’s Lynparza drug approved by US FDA for pancreatic cancer
“Lynparza is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer," said AstraZeneca's Dave Fredrickson.
AstraZeneca and Daiichi Sankyo's breast cancer treatment gets US approval
AstraZeneca and Daiichi Sankyo are exploring the further potential of Enhertu in HER2-breast cancer with three ongoing Phase III trials
AstraZeneca sells rights to breast, prostate cancer drugs for US$181mln
The FTSE 100-listed firm already sold commercial rights in the US in 2017, while now the drugs have lost exclusive rights in most countries in Europe and Africa